GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study

Design
Retrospective cohort
Drugs
Class unspecified
Assessment
Not yet reviewed by a person · added Oct 18, 2026

This study was added automatically and has not been reviewed. Until it is, the collection publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved.

01Source

The source, as retrieved

Abstract

[BACKGROUND] Hidradenitis suppurativa (HS) is associated with obesity, metabolic dysfunction and increased healthcare utilization. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated anti-inflammatory effects and reduction in HS symptoms, but real-world patterns of GLP-1RA use in HS remain limited. [OBJECTIVES] To investigate GLP-1RA use and comorbidity burden among patients with HS compared to matched psoriasis patients and background controls, including changes in healthcare utilization and treatment patterns following GLP-1RA initiation. [METHODS] In this nationwide Danish register-based cohort study, adult patients with HS and age- and sex-matched patients with psoriasis and background controls were included from 1 January 2000 to 31 December 2022. Comorbidities were assessed at the date of HS diagnosis (index date) and at GLP-1RA initiation. Healthcare utilization, surgical procedures and medication use were examined during the 2 years before and after GLP-1RA initiation among patients with HS receiving continuous GLP-1RA treatment and matched HS non-users. [RESULTS] A total of 12,581 patients with HS, 9824 patients with psoriasis, and 12,581 controls were included. During follow-up, 8.2% of patients with HS initiated GLP-1RA treatment, compared with 5.7% of psoriasis patients and 3.2% of controls. Mean time to GLP-1RA initiation was shorter among patients with HS (8.88 years) than psoriasis patients (10.1 years; p < 0.001) and controls (10.2 years; p < 0.001). Cardiometabolic and psychiatric comorbidities increased from index date to treatment initiation across all groups. Following GLP-1RA initiation, lower rates of surgical procedures and systemic medication use were observed. [CONCLUSIONS] Patients with HS demonstrated earlier and more frequent use of GLP-1RA compared with psoriasis patients and controls, with decreased use of HS-specific treatments and surgical procedures following GLP-1RA initiation. Comparable declines were observed among matched non-initiators.

Where this record came from

SourceRetrievedIdentifier
pubmedOct 4, 202642828450
first ingestion
pubmedOct 4, 202642828450
duplicate matched on doi
pubmedOct 4, 202642828450
duplicate matched on doi
pubmedOct 4, 202642828450
duplicate matched on doi
pubmedOct 11, 202642828450
duplicate matched on doi
pubmedOct 11, 202642828450
duplicate matched on doi
pubmedOct 11, 202642828450
duplicate matched on doi
pubmedOct 11, 202642828450
duplicate matched on doi
pubmedOct 18, 202642828450
duplicate matched on doi
pubmedOct 18, 202642828450
duplicate matched on doi
pubmedOct 18, 202642828450
duplicate matched on doi
pubmedOct 18, 202642828450
duplicate matched on doi